iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
Sofosbuvir+Valpatasvir FDA Approval is expected....
  "Gilead filed the NDA for SOF/VEL on October 28, 2015, and FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of June 28, 2016."
in phase 3 is
in phase 3 is SOF/velpatasvir/GS-9857.....
Next coming is Merck's triple regimen.....
EASL:High Efficacy of an 8-Week, 3-Drug Regimen of MK-3682/Grazoprevir/MK-8408 in HCV Genotype 1, 2, or 3-Infected Patients: SVR24 Data from the Phase 2 C-CREST 1 and 2 Studies - (04/19/16)
And J&J's triple
https://clinicaltrials.gov/ct2/show/NCT02569710?term=al-335&rank=2........J&J HCV Update: AL335+ACH3102+Simeprevir Phase 2 Study - (05/06/16)
Merck's Zepatier was FDA approved early in 2016 and is now available.
EASL: Sofosbuvir/Velpatasvir in Combination With Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study - (04/15/16)
EASL: Sofosbuvir/Velpatasvir for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy - (04/22/16)
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - (12/08/15)
EASL: Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination - (04/21/16)
High Efficacy of Sofosbuvir/Velpatasvir Across 7 HCV Genotypes and 46 Subtypes: Pooled Data From the ASTRAL1, 2 and 3 Trials (12/14/15)
High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials (12/14/15)
Sofosbuvir Plus Velpatasvir (GS-5816) Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial - (11/17/15) published
AASLD: Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV-Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study - (11/30/15)
EASL: Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study - (05/27/16)
EASL: Sofosbuvir / Velpatasvir.... + GS-9857 - (05/05/16)
EASL: Newest HCV Drugs at EASL - (05/05/16)
EASL: ABT-493 + ABT-530 at EASL - (05/05/16)
The International Liver Congress™
EASL - European Association for the
Study of the Liver

Barcelona, Spain
13-17 April 2016
  iconpaperstack View Older Articles   Back to Top   www.natap.org